4564.T
OncoTherapy Science,Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 22.00
+4.76%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 784.0M | 808.0M | 750.0M | 610.0M | 1.1B |
| Cost of Revenue | 755.7M | 794.6M | 762.8M | 787.8M | 1.1B |
| Gross Profit | 28.3M | 13.4M | (12.8M) | (177.8M) | 40.8M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 307.0M | 289.4M | 294.1M | 265.0M | 431.6M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 307.0M | 289.4M | 294.1M | 265.0M | 431.6M |
| Cost and Expenses | 1.6B | 1.6B | 1.5B | 1.7B | 2.2B |
| Operating Income (EBIT) | (793.0M) | (810.0M) | (797.0M) | (1.1B) | (1.1B) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 1.3M | 1.3M | 1.2M | 218.0K | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | (24.7M) | (35.4M) | (17.1M) | (15.6M) | (26.7M) |
| Non-Operating Income (excl Interest) | 446.0K | — | 50.0K | 6.0K | 357.0K |
| EBT (Pre-Tax Income) | (879.5M) | (908.5M) | (813.1M) | (1.3B) | (1.1B) |
| Income Tax Expense | 2.2M | 2.2M | 2.2M | 2.4M | 2.2M |
| Bottom Line | |||||
| Net Income | (881.0M) | (910.0M) | (815.0M) | (1.3B) | (1.1B) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (881.0M) | (910.0M) | (815.0M) | (1.3B) | (1.1B) |
| Per Share | |||||
| Basic EPS | (¥3) | (¥3) | (¥3) | (¥6) | (¥6) |
| Diluted EPS | (¥3) | (¥3) | — | — | — |
| Revenue Per Share | ¥3 | ¥2 | ¥3 | ¥3 | ¥6 |
| Shares | |||||
| Basic Shares Outstanding | 311.0M | 328.2M | 261.1M | 212.8M | 192.6M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | — | — | — | — |
| D&A | — | — | — | — | — |
| EBIT | (793.0M) | (810.0M) | (797.0M) | (1.1B) | (1.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026